Logo image of PHARM.AS

PHARMING GROUP NV (PHARM.AS) Stock Fundamental Analysis

AMS:PHARM - Euronext Amsterdam - NL0010391025 - Common Stock - Currency: EUR

0.792  0 (-0.56%)

Fundamental Rating

4

PHARM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 71 industry peers in the Biotechnology industry. PHARM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PHARM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year PHARM has reported negative net income.
PHARM had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PHARM reported negative net income in multiple years.
In multiple years PHARM reported negative operating cash flow during the last 5 years.
PHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFPHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

PHARM has a better Return On Assets (-2.96%) than 64.79% of its industry peers.
The Return On Equity of PHARM (-5.36%) is better than 69.01% of its industry peers.
Industry RankSector Rank
ROA -2.96%
ROE -5.36%
ROIC N/A
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
PHARM.AS Yearly ROA, ROE, ROICPHARM.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

PHARM has a Gross Margin of 88.09%. This is amongst the best in the industry. PHARM outperforms 87.32% of its industry peers.
In the last couple of years the Gross Margin of PHARM has remained more or less at the same level.
PHARM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
PHARM.AS Yearly Profit, Operating, Gross MarginsPHARM.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

PHARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHARM has more shares outstanding
Compared to 5 years ago, PHARM has more shares outstanding
Compared to 1 year ago, PHARM has an improved debt to assets ratio.
PHARM.AS Yearly Shares OutstandingPHARM.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
PHARM.AS Yearly Total Debt VS Total AssetsPHARM.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 0.53, we must say that PHARM is in the distress zone and has some risk of bankruptcy.
PHARM has a Altman-Z score (0.53) which is in line with its industry peers.
PHARM has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
PHARM has a Debt to Equity ratio of 0.48. This is comparable to the rest of the industry: PHARM outperforms 53.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z 0.53
ROIC/WACCN/A
WACC6.45%
PHARM.AS Yearly LT Debt VS Equity VS FCFPHARM.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

PHARM has a Current Ratio of 3.77. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.77, PHARM is doing good in the industry, outperforming 76.06% of the companies in the same industry.
PHARM has a Quick Ratio of 3.02. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PHARM (3.02) is better than 70.42% of its industry peers.
Industry RankSector Rank
Current Ratio 3.77
Quick Ratio 3.02
PHARM.AS Yearly Current Assets VS Current LiabilitesPHARM.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for PHARM have decreased strongly by -50.00% in the last year.
The Revenue has grown by 21.15% in the past year. This is a very strong growth!
PHARM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.64% yearly.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%225%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%14.1%

3.2 Future

The Earnings Per Share is expected to grow by 52.28% on average over the next years. This is a very strong growth
PHARM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.40% yearly.
EPS Next Y183.09%
EPS Next 2Y10.31%
EPS Next 3Y46.06%
EPS Next 5Y52.28%
Revenue Next Year13.39%
Revenue Next 2Y11.6%
Revenue Next 3Y10.41%
Revenue Next 5Y8.4%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PHARM.AS Yearly Revenue VS EstimatesPHARM.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
PHARM.AS Yearly EPS VS EstimatesPHARM.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.1 -0.1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHARM. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 45.05, PHARM can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, PHARM is valued cheaply inside the industry as 80.28% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.81, PHARM is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 45.05
PHARM.AS Price Earnings VS Forward Price EarningsPHARM.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -14.33
PHARM.AS Per share dataPHARM.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PHARM's earnings are expected to grow with 46.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.31%
EPS Next 3Y46.06%

More info and screens

0

5. Dividend

5.1 Amount

PHARM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMING GROUP NV

AMS:PHARM (5/5/2025, 5:29:31 PM)

0.792

0 (-0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2025-03-13/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners15.1%
Inst Owner ChangeN/A
Ins Owners1.49%
Ins Owner ChangeN/A
Market Cap54.17M
Analysts88.57
Price Target6.14 (675.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.45%
Min EPS beat(2)-27.22%
Max EPS beat(2)22.33%
EPS beat(4)1
Avg EPS beat(4)-141.37%
Min EPS beat(4)-363.52%
Max EPS beat(4)22.33%
EPS beat(8)3
Avg EPS beat(8)-79.95%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.95%
Min Revenue beat(2)-5.54%
Max Revenue beat(2)11.43%
Revenue beat(4)1
Avg Revenue beat(4)-4.65%
Min Revenue beat(4)-21.13%
Max Revenue beat(4)11.43%
Revenue beat(8)4
Avg Revenue beat(8)-2.24%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.96%
PT rev (3m)-14.17%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-50%
EPS NY rev (1m)156.12%
EPS NY rev (3m)243.41%
Revenue NQ rev (1m)5.84%
Revenue NQ rev (3m)5.84%
Revenue NY rev (1m)3.82%
Revenue NY rev (3m)3.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 45.05
P/S 0.21
P/FCF N/A
P/OCF N/A
P/B 0.28
P/tB 0.38
EV/EBITDA -14.33
EPS(TTM)-0.02
EYN/A
EPS(NY)0.02
Fwd EY2.22%
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS3.83
BVpS2.85
TBVpS2.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.96%
ROE -5.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.09%
FCFM N/A
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score3
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA 14.11
Cap/Depr 4.95%
Cap/Sales 0.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.77
Quick Ratio 3.02
Altman-Z 0.53
F-Score3
WACC6.45%
ROIC/WACCN/A
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%225%
EPS Next Y183.09%
EPS Next 2Y10.31%
EPS Next 3Y46.06%
EPS Next 5Y52.28%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%14.1%
Revenue Next Year13.39%
Revenue Next 2Y11.6%
Revenue Next 3Y10.41%
Revenue Next 5Y8.4%
EBIT growth 1Y67.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.21%
EBIT Next 3Y79.98%
EBIT Next 5Y85.48%
FCF growth 1Y86.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.63%
OCF growth 3YN/A
OCF growth 5YN/A